Treadwell Announces Ocifisertib, a First-in-Class PLK4 Inhibitor, has Received Orphan Designation from U.S. FDA for the Treatment of Acute Myeloid Leukemia

TORONTO& SAN FRANCISCO–(BUSINESS WIRE) February 20, 2024–Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials